Group 1 - The core viewpoint of the news is the active trading of the newly listed Hua Bao Hang Seng Hong Kong Stock Connect Innovative Drug Selected ETF, with Barclays Bank being the largest shareholder [2] - The ETF tracks the Hang Seng Hong Kong Stock Connect Innovative Drug Selected Index, which consists of 30 innovative drug companies listed in Hong Kong, and was launched in July 2023 [2] - The index has a rolling price-to-earnings ratio of 28 times, which is at approximately the 16th percentile of its historical range since its inception [2] Group 2 - Hua Bao Fund, established in 2003, has a shareholder structure where Chinese shareholder Hua Bao Trust holds 51%, foreign shareholder Warburg Pincus Asset Management holds 29%, and Jiangsu Railway Group holds 20% [3] - The company has a healthy corporate culture due to its market-oriented approach in selecting management, avoiding nepotism [5] - Hua Bao Fund has focused on ETFs as a key direction, achieving over 90 billion yuan in equity ETF scale, with notable products like the Financial Technology ETF and Medical ETF [6]
基金忠言｜外资巨头重仓ETF，华宝基金榜上有名
Sou Hu Cai Jing·2025-07-14 01:20